Addex Pharmaceuticals (SWISS: ADXN) announced that it has decided to end prematurely the migraine prevention study 206. Routine safety monitoring of blinded data in study 206 has revealed an incidence of abnormalities of liver function tests that is higher than expected in this population. The...